Overview A Study of KM501 in Patients With Solid Tumors Status: Not yet recruiting Trial end date: 2027-12-01 Target enrollment: Participant gender: Summary A single-arm, open, multicenter Phase I study to evaluate the safety, tolerability, pharmacokinetic profile, and efficacy of the KM501 double-antibody ADC in subjects with advanced solid tumors that express, amplify, or mutate HER2 Phase: Phase 1 Details Lead Sponsor: Xuanzhu Biopharmaceutical Co., Ltd.